Aberdeen Group
SGP

Aberdeen Group’s SpyGlass Pharma SGP Stock Holding History

Aberdeen Group’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11M Buy
493,076
+272,622
+124% +$5.91M 0.02% 578
2026
Q1 		$5.71M Buy
+220,454
New +$5.93M 0.01% 675

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Aberdeen Group's SGP Position: Q2 2026 in Review

Aberdeen Group increased its SpyGlass Pharma (SGP) stake by 124% in Q2 2026, buying an estimated $5.91M and bringing the position to 493,076 shares worth $11M. The position accounts for 0.02% of the portfolio, ranked #578.

Aberdeen Group first reported a position in SGP in Q1 2026 and has held it in 2 quarters since. 52 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

  • Aberdeen Group held 493,076 shares of SpyGlass Pharma worth $11M as of Q2 2026.
  • Aberdeen Group bought 272,622 SpyGlass Pharma shares in Q2 2026, an estimated $5.91M.
  • SpyGlass Pharma made up 0.02% of Aberdeen Group's portfolio in Q2 2026, its #578 holding.
  • Aberdeen Group first reported a position in SpyGlass Pharma in Q1 2026 and has held it in 2 quarters since.
  • 52 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.